AGIOS PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Payments to Acquire Marketable Securities of $430.62 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2020-11-05
- AGIOS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2020-09-30 was $241.02M, a 376.41% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2020-06-30 was $134.69M, a 101.60% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2020-03-31 was $54.91M, a 29.07% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2019-09-30 was $50.59M, a 68.91% decline year-over-year.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month |
|---|---|---|---|
| 2020-09-30 | $241.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $375.71M derived: sum of 2 quarters · filed 2020-11-05 | $430.62M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $134.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $189.60M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $54.91M 10-Q · filed 2020-04-30 | ||
| 2019-09-30 | $50.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $117.40M derived: sum of 2 quarters · filed 2020-11-05 | $194.82M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $66.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $144.23M 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $77.42M 10-Q · filed 2020-04-30 | ||
| 2018-09-30 | $162.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $424.40M derived: sum of 2 quarters · filed 2019-10-31 | $755.37M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $261.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $592.66M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $330.97M 10-Q · filed 2019-05-02 | ||
| 2017-09-30 | $135.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $577.78M derived: sum of 2 quarters · filed 2018-11-01 | $604.52M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $441.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $468.56M 10-Q · filed 2018-08-02 | |
| 2017-03-31 | $26.74M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |